CancerQuest | Interview with Dr. Fadlo Khuri

Dr. Fadlo Khuri
Deputy Director for Clinical and Translational Research
Chair and Blomeyer Professor of Hematology and Oncology
co-Director, Cancer Drug Discovery, Development, and Delivery Program
Professor of Otolaryngology & Medicine and Pharmacology,
Chief Medical Officer at Winship Cancer Institute
Emory University

Dr. Khuri is a clinician/researcher who focuses on developing novel targeted agents to treat and prevent cancer, with an emphasis on lung cancer. In the interview, Dr. Khuri discusses his work on the development of a drug that would target a process (called farneylation) that helps to activate a set of oncogenes.

Questions and Answers

	About Dr. Khuri(Time: 6 sec)
	Why did you become interested in tobacco related cancer research?(Time: 46 sec)
	What projects in the past have led to what you are doing now?(Time: 27 sec)
	What are small molecule inhibitors?(Time: 1 min 1 sec)
	In your research, do you focus on treatment or prevention?(Time: 40 sec)
	What is the funtion of farnesyltransferase and how is it related to cancer?(Time: 2 min 21 sec)
	How do farnesyltransferase inhibitors (FTI) work?(Time: 29 sec)
	At what stage is your reasearch on farnesyltransferase inhibitors?(Time: 1 min 3 sec)
	How do you target FTIs to cancer cells?(Time: 1 min 3 sec)
	What is an oncogene?(Time: 53 sec)
	What is the future of FTI?(Time: 1 min 59 sec)
	How does FTI treatment differ from chemotherapy?(Time: 1 min 21 sec)
	What led to your focus on prevention?(Time: 1 min 47 sec)
	What are retinoids?(Time: 1 min 34 sec)
	Can you describe more about the research team at Winship Cancer Institute?(Time: 1 min 9 sec)